A meta-analysis by Filette et al. reported that the incidence of hypophysitis with CTLA-4 inhibitors is 5.6%, PD-1/PD-L1 inhibitors is 0.5%, and combination therapy with CTLA-4 inhibitor and PD-1 inhibitor is 10.5% [59]. The gene discussed is CD274; the disease is hypophysitis.